Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib vs Investigator Choice of BTK Inhibitor in Previously Treated Mantle Cell Lymphoma
NCT04662255Phase 3Active, not recruiting
- Sponsor
- Loxo Oncology
- Start
- Apr 2021
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of pirtobrutinib in mantle cell lymphoma (MCL), sponsored by Loxo Oncology. Started Apr 2021; status: active, not recruiting.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04662255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662255.